Quinolones in sexually transmitted diseases. State of the art

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 92-95

  Ridgway, Geoffrey L ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; CHLAMYDIA TRACHOMATIS; CONFERENCE PAPER; HUMAN; MYCOPLASMA; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; SEXUALLY TRANSMITTED DISEASE;

4-QUINOLONES; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

CHLAMYDIA TRACHOMATIS; MYCOPLASMA; MYCOPLASMATALES; NEISSERIA; NEISSERIA GONORRHOEAE;

EID: 0032729625     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00018     Document Type: Conference Paper

References (33)

1. Ridgway GL. Quinolones in sexually transmitted diseases. Global experience. Drugs 1995; 49 Suppl. 2: 115-22
2. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998; 47 (No. RR-1)
3. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-51
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-38. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998
5. Tapsall JW, Limnios EA, Shultz TR. Continuing evolution of the pattern of quinolone resistance in Neisseria gonorrhoeae isolated in Sydney, Australia. Sex Transm Dis 1998; 25: 415-7
6. Gordon SM, Carlyn CJ, Doyle LJ, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors. Ann Intern Med 1996; 125: 465-70
7. Knapp JS. Neisseria gonorrhoeae resistant to ciprofloxacin and ofloxacin. Sex Transm Dis 1998; 25: 425-6
8. Ng PP, Chan RK, Ling AE. Gonorrhoea treatment failure and ciprofloxacin resistance. Int J STD AIDS 1998; 9: 323-5
9. Deguchi T, Saito I, Tanaka M, et al. Fluoroquinolone treatment failure in gonorrhoea. Sex Transm Dis 1997; 24: 247-50
10. Tanaka M, Takahashi K, Saika T, et al. Development of fluoroquinolone resistance and mutations involving Gyr A and Par C proteins among Neisseria gonorrhoeas isolates in Japan. J Urol 1998; 159: 2215-9
11. Carlyn CJ, Doyle LJ, Knapp CC, et al. Activity of three investigational fluoroquinolones (BAY y 3118, DU 6859a, and clinafloxacin) against Neisseria gonorrhoeae with diminished susceptibilities to ciprofloxacin and ofloxacin. Antimicrob Agents Chemother 1995; 39: 1606-8
12. Deguchi T, Yasuda M, Nakano M, et al. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the Gyr A subunit of DNA gyrase and the Par C subunit of topoisomerase IV. J Antimicrob Chemother 1997; 39: 247-9
13. Moi H, Morel P, Gianotti B, et al. Comparative efficacy of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. J Antimicrob Chemother 1996; 37 Suppl. A: 115-22
14. Hook III EW, McCormack WM, Martin D, et al. Comparison of single dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhoea in men. Antimicrob Agents Chemother 1997; 41: 1843-5
15. Mroczkowski TS, Hook III EW, McCormack WM, et al. The efficacy and safety of single dose grepafloxacin 400mg in the treatment of uncomplicated gonococcal cervicitis in females: comparison with single dose cefixime 400mg [abstract P411]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25-28: Lausanne, Switzerland
16. Jones RB, Schwebke J, Thorpe Jr EM, et al. Randomized trial of trovafloxacin and ofloxacin for single dose therapy of gonorrhoea. Trovafloxacin Study Group. Am J Med 1998; 104: 28-32
17. Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6
18. Niki Y, Miyashita N, Kubota Y, et al. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Antimicrob Agents Chemother 1997; 41: 857-9
19. Miyashita N, Kishimoto T, Nakajima M, et al. In vitro and in vivo activities of HSR-903, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-4
20. Wise R, Brenwald NP, Andrews JM, et al. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. J Antimicrob Chemother 1997; 39: 447-52
21. Felmingham D, Robbins MJ, Ingley K, et al. In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39 Suppl. B: 43-9
22. Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 63-5
23. Ridgway GL, Salman H, Robbins MJ, et al. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; 40 Suppl. A: 31-4
24. Ridgway GL, Salman H, Clark S, et al. SB-265805 (LB20304a): comparative in vitro activity against Legionella pneumophila and Chlamydia spp. [abstract number F-97]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-28: San Diego, California. Washington, DC: American Society for Microbiology, 1998
25. Dessus-Babus S, Bébéar C, Charon A, et al. Sequencing of gyrase and topoisomerase IV quinolone-resistance determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2474-81
26. Bébéar CM, Renaudin H, Boudjadja A, et al. In vitro activity of Bay 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 1998; 42: 703-4
27. Bébéar CM, Renaudin H, Charo A, et al. Alterations in topoisomerase IV and DNA gyrase in quinolone resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2304-11
28. Phillips I, Dimian C, Barlow D, et al. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1996; 37 Suppl. A: 123-34
29. McCormack WM, Martin DH, Hook III EW, et al. Daily oral grepafloxacin vs twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection. Infect Dis Obstet Gynecol 1998; 6: 109-15
30. Pfizer. Treatment of endocervical chlamydial infection with trovafloxacin. 1998. Data on file
31. Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24: 170-8
32. Pfizer. Treatment of pelvic inflammatory disease with trovafloxacin. 1998. Data on file
33. Ahmed BA, Tang A. Successful treatment of donovanosis with ciprofloxacin. Genitourin Med 1996; 72: 73-4